Aspen enriches Parkinson’s cell therapy trial with Kite-backed $115M series C
Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease. The…